News

Teva, Parkinson’s Unity Walk launch public awareness campaign to support Parkinson’s disease patients

BY Michael Johnsen

FRAZER, Pa. — Teva Pharmaceuticals and the Parkinson’s Unity Walk on Friday announced the launch of a public awareness campaign, "CommUNITY: Carrying the PD Torch," to support Parkinson’s disease patients during Parkinson’s Disease Awareness Month in April. The campaign aims to empower patients to set their goals and work to achieve them by uniting the community and encouraging patients in their PD journey.

The "CommUNITY: Carrying the PD Torch," campaign kicked off on April 2 in Philadelphia at the Rocky monument, which was blanketed in tulips, the worldwide symbol of PD. A Parkinson’s disease patient, Susan Battagliese, was onsite to share her experience with Parkinson’s disease and Daniel Kremens, Jefferson University Hospital Physician and Co-Director, Movement Disorders Program, spoke on recent developments in PD. 

The campaign will culminate at the 20th Annual Parkinson’s Unity Walk in Central Park on April 26, where a torch of tulips will be brought from the Rocky monument to the Teva booth at the Walk. The Parkinson’s Unity Walk is the largest grassroots fundraiser for Parkinson’s research in the country and 100% of donations support research funded by seven major Parkinson’s organizations. 

"We’re extremely pleased to partner with Teva during PD Awareness Month," stated Carol Walton, CEO of The Parkinson Alliance, the umbrella organization for the Parkinson’s Unity Walk. "It’s important to bring together patients and educate the community about PD."

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

B-lēve skin care hits grocers’ beauty shelves

BY Antoinette Alexander

NEW YORK — Several grocers have expanded their beauty selection by offering the new b-lēve skin care, formulated with proprietary natural grape extract technology to help battle aging skin.  


“We wanted to bring the same kind of quality skin care available in the prestige marketplace to the local grocer, making it easy for women to find the products they want in a shopping environment that is a part of their daily lives. Our products reflect that initial goal, with truly effective ingredients like grape extracts that are proven via clinical studies to be powerful anti-agers,” stated Tony Harrington, director of business management for b-lēve.
 
Ranging from cleansers to moisturizers and serums, the line is paraben free, hypo-allergenic and animal friendly. 


The b-lēve skin care collection includes:


  • b-luminous Facial Cleanser (suggested retail price $6.99)
  • b-vibrant Rejuvenating Day Lotion SPF 15 (SRP $18.99)
  • b-youthful Face & Eye Serum (SRP $19.99)
  • b-restful Rejuvenating Night Cream (SRP $18.99)
  • b-nourished Facial Cleansing Cloths (SRP $3.99)
  • b-bright Eye Roll-On (SRP $14.99)

All b∙lēve products are available at b-lēve.com and such grocers as Coborn’s, Giant Eagle and Hy-Vee.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Mylan’s Frova ANDA moves forward following settlement agreement with Endo Pharmaceuticals

BY Michael Johnsen

PITTSBURGH — Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan’s filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg. This product is the generic version of Frova, which is used to treat acute migraine headaches in adults. 

As a result of the decision, the Court has vacated its Jan. 28, 2014, decision in favor of Endo regarding the parties’ patent litigation over this product, which could have prevented Mylan from launching its generic version of Frova until after the expiration of U.S. Patent 5,464,864 patent on Nov. 7, 2015. By enforcing the settlement, Mylan can launch its product pursuant to the terms of the settlement, contingent upon final FDA approval.

For the 12 months ended Dec. 31, 2013, frovatriptan had U.S. sales of approximately $66.4 million, according to IMS Health.

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?